Taken together, the findings of this study demonstrated that LTF acted as an oncogenic regulator in GBM by promoting NF-κB signaling pathway activation, extending knowledge on the molecular mechanism of GBM progression and providing new potential therapeutic targets for GBM treatment. This evidence concerns the gene NFKB1 and glioblastoma.